/
Oncology
Endometrial Cancer
105
Pipeline Programs↗
178
Active Trials↗
75
Companies Involved↗
Endometrial Cancer is a highly competitive landscape with 105 programs across 75 companies. The most active players are Roche, Incyte, Sichuan Baili Pharmaceutical Co., Ltd.. 23 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 17
Phase 261
Phase 323
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
72 of 97 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 97 classified programs, each share of the total. Modality classified for 94% of 105 pipeline programs.
Analysis
Trial Status
412
clinical trials
Completed145 · 35%
Recruiting89 · 22%
Active, not recruiting50 · 12%
Unknown status40 · 10%
Not yet recruiting38 · 9%
Terminated31 · 8%
Other19 · 5%
Clinical Trials
Trial Activity
412 trials
Open-Label Phase II Trial of Enfortumab Vedotin in Recurrent or Persistent Endometrial Carcinoma
Recruiting·—·Phase 2·NCT07139977·12 enrolled
Page 1 of 28
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)